Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) headquartered in Watertown, will host a conference call for the investment community to discuss the 4Q20 financial results on 23rd November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.enanta.com
To participate on the live call, please dial 855-840-0595 (United States) or 518-444-4814 Toll Number
Earnings Expectation
Enanta Pharmaceuticals, Inc. is reporting fourth quarter financial results on Monday 23rd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ENTA is expected to report 4Q20 loss of $ 0.95 per share from revenue of $ 25.74 million.
For the full year, analysts anticipate top line of $ 124.61 million, while looking forward to loss of $ 1.3 per share bottom line.
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc.
